228. 閉塞性細気管支炎 Bronchiolitis obliterans Clinical trials / Disease details
臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05413356 (ClinicalTrials.gov) | June 1, 2022 | 7/6/2022 | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation | Bronchiolitis Obliterans Syndrome;Hematologic Malignancy | Drug: Ruxolitinib | First Affiliated Hospital of Zhejiang University | Second Affiliated Hospital, School of Medicine, Zhejiang University;Zhejiang Provincial People's Hospital;The First Affiliated Hospital of Zhejiang Chinese Medical University;Sir Run Run Shaw Hospital;First Affiliated Hospital of Wenzhou Medical University;Ningbo No. 1 Hospital;The Affiliated People's Hospital of Ningbo University;Jinhua Central Hospital;Taizhou Hospital;Union hospital of Fujian Medical University;Xiangya Hospital of Central South University | Recruiting | 18 Years | 65 Years | All | 50 | Phase 2 | China |
| 2 | NCT04908735 (ClinicalTrials.gov) | November 12, 2021 | 26/5/2021 | Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant | Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study | Hematopoietic Stem Cell Transplant (HSCT);Bronchiolitis Obliterans (BO) | Drug: Ruxolitinib | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 5 Years | 25 Years | All | 40 | Phase 2 | United States |
| 3 | NCT03674047 (ClinicalTrials.gov) | April 19, 2019 | 14/9/2018 | Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | Other Cancer | Drug: ruxolitinib | Massachusetts General Hospital | Incyte Corporation | Recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | United States |